2024
Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkers
2023
Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine
Rosell D, Slifstein M, Thompson J, Xu X, Perez-Rodriguez M, McClure M, Hazlett E, New A, Nabulsi N, Huang Y, Carson R, Siever L, Abi-Dargham A, Koenigsberg H. Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine. Psychopharmacology 2023, 240: 361-371. PMID: 36640190, DOI: 10.1007/s00213-022-06306-2.Peer-Reviewed Original ResearchConceptsAnterior cingulate cortexAnti-aggressive effectsIED patientsPositron emission tomographyVentral striatumTransporter availabilityChildhood traumaSerotonin transporter availabilityRational treatment selectionIntermittent explosive disorderFluoxetine 20Fluoxetine treatmentSerotonergic abnormalitiesHealthy comparison participantsTreatment selectionRisk individualsObjectivesThe aimPatientsCingulate cortexExplosive disorderEmission tomographyImpulsive aggressionNovel therapeuticsFluoxetineNeuroanatomical basis
2019
Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB
Sanchez-Rangel E, Gallezot JD, Yeckel CW, Lam W, Belfort-DeAguiar R, Chen MK, Carson RE, Sherwin R, Hwang JJ. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. International Journal Of Obesity 2019, 44: 964-967. PMID: 31636373, PMCID: PMC7259982, DOI: 10.1038/s41366-019-0471-4.Peer-Reviewed Original ResearchConceptsBrown adipose tissueDetectable brown adipose tissueDistribution volume ratioMultilinear reference tissue model 2Norepinephrine transporterSympathetic innervationNorepinephrine transporter availabilityHuman brown adipose tissueDense sympathetic innervationPET-CT imagingReference tissue model 2Human PET studiesSupraclavicular regionCaucasian womenTransporter availabilityOccipital cortexObesityTherapeutic targetAdipose tissueBrown fatPET studiesWomenInnervationSelective ligandsEnergy-dissipating properties